Jan 01,2020

Mahana Therapeutics gears up to launch IBS treatment app with $61M series B, reaching to total of $81M funding

Not long after the FDA cleared the smartphone version of Mahana IBS, investors led by JAZZ Venture Partners and Gurnet Point Capital contributed $61 million in series B funding to help commercialize the startup’s IBS program and support its continued work to develop digital therapeutics for other chronic diseases. JAZZ also led Mahana’s previous funding rounds alongside Lux Capital; in total, the San Francisco-based company has raised $81 million since its founding.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Jul 25,2023

Better Therapeutics Announces $6.7 Million in New Financing at an Average Price of $0.77 per Share

Better Therapeutics raised $6.7 million through equity offerings to support the launch of AspyreRx™, a prescription-only digital therapy for adults with type 2 diabetes, as a result of the issuance of 2,023,583 shares of its common stock under its At-The-Market program at an average price per share of $1.19.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Jul 25,2023

Better Therapeutics Announces $6.7 Million in New Financing at an Average Price of $0.77 per Share

Better Therapeutics raised $6.7 million through equity offerings to support the launch of AspyreRx™, a prescription-only digital therapy for adults with type 2 diabetes, as a result of the issuance of 2,023,583 shares of its common stock under its At-The-Market program at an average price per share of $1.19.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Jun 15,2023

Wellthy Therapeutics adds Beyond Next Ventures as an investor; Expands into Japan

Wellthy Therapeutics is proud to announce that it has secured additional financing, led by Beyond Next Ventures, a venture capital firm based in Japan, with participation from existing investors. This paves the way for Wellthy Therapeutics to expand its platform into the Japanese market, enabling enterprise customers to deploy world class digital health solutions to support patients globally. "We started Wellthy Therapeutics with a vision that one day, nobody would die from preventable disease complications. We are humbled by the confidence placed in us by Beyond Next Ventures, and are excited by the opportunity to further accelerate our vision of impacting 10 million patients in this decade, by helping Japanese life science and healthcare enterprise customers achieve better real-world outcomes," said Abhishek Shah, CEO of Wellthy Therapeutics.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Feb 23,2023

Notable Labs and VBL Therapeutics Merger Generates $10 Million Funding

VBL Therapeutics (Nasdaq:VBLT), a biotechnology company developing targeted medicines for immune-inflammatory diseases, and Notable Labs, Inc. (“Notable”), a clinical stage therapeutic platform company developing predictive precision medicines for cancer patients, today announced they have entered into a definitive merger agreement. Concurrent with the execution of the merger agreement, a healthtech-focused investor syndicate, including existing Notable stockholders Builders VC, B Capital Group, Y Combinator, First Round Capital, and Founders Fund, have entered into a definitive securities purchase agreement with Notable to invest $10.3 million in gross proceeds prior to the close of the proposed merger. After completion of the merger, the combined company is expected to be capitalized with a cash runway into 2025.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Aug 09,2016

Analytics startup Biofourmis gets US$1M funding led by SpesNet

Biofourmis, Singapore-based personalised physiological data analytics firm, today announced that the company has secured US$1 million in angel funding, led by SpesNet and Eden Strategy. Biofourmis has been actively working with the healthcare sector to offer predictive, precise and meaningful insights into one’s health.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Dec 22,2017

Acceptance of capital from Japan Post Group

Tokyo-based company, Wellby, which supports the health management of people facing illnesses, has announced that it will carry out a third-party allotment of shares to Japan Post Capital Co., Ltd. and proceed with a partnership with Japan Post Group. By utilizing Japan Post Group's brand and network, Wellby aims to further promote the use of PHR and contribute to medical institutions, regions, and municipalities.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Apr 20,2014

Welby Inc. announced that it has received funding from Dentsu Innovation Partners Inc.

Welby Inc. announced that it has received a round of funding from new investor Dentsu Digital Investment Business Limited Partnership, a fund managed by Dentsu Innovation Partners Inc. on April 21, 2014. The company issued shares by third-party allocation to the investor.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Apr 21,2014

Welby Inc. announced that it has received funding from Dentsu Innovation Partners Inc.

Welby Inc. announced that it has received a round of funding from new investor Dentsu Digital Investment Business Limited Partnership, a fund managed by Dentsu Innovation Partners Inc. on April 21, 2014. The company issued shares by third-party allocation to the investor.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
May 26,2015

GNS Healthcare Secures $8.1M in venture round

GNS Healthcare (Aitia) received $8.1M venture funding from the investors according to the SEC form registered.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Subscribe to FUNDING ROUND